EyePoint Pharmaceuticals, Inc.
General ticker "EYPT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $586.7M (TTM average)
EyePoint Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 54.0%.
Estimated limits based on current volatility of 3.8%: low 15.22$, high 16.42$
Factors to consider:
- Total employees count: 165 (+36.4%) as of 2024
- US accounted for 97.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Cybersecurity threats, DOJ subpoena and enforcement actions, Technological obsolescence, Intellectual property risks
- Current price 139.3% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.13$, 8.64$]
- 2025-12-31 to 2026-12-31 estimated range: [2.28$, 6.30$]
Financial Metrics affecting the EYPT estimates:
- Positive: with PPE of -3.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -30.81 <= 0.04
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of -2.77 <= -0.76
- Positive: Shareholder equity ratio, % of 80.41 > 64.17
Short-term EYPT quotes
Long-term EYPT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $41.40MM | $46.02MM | $43.27MM |
| Operating Expenses | $141.04MM | $121.08MM | $189.13MM |
| Operating Income | $-99.64MM | $-75.07MM | $-145.85MM |
| Non-Operating Income | $-2.62MM | $4.36MM | $15.07MM |
| Interest Expense | $3.19MM | $1.25MM | $0.01MM |
| R&D Expense | $49.64MM | $64.66MM | $132.93MM |
| Income(Loss) | $-102.25MM | $-70.71MM | $-130.78MM |
| Taxes | $0.00MM | $0.08MM | $0.09MM |
| Profit(Loss)* | $-102.25MM | $-70.80MM | $-130.87MM |
| Stockholders Equity | $96.37MM | $266.32MM | $336.50MM |
| Inventory | $2.89MM | $3.91MM | $2.31MM |
| Assets | $180.36MM | $355.18MM | $418.46MM |
| Operating Cash Flow | $-65.00MM | $1.88MM | $-126.23MM |
| Capital expenditure | $2.15MM | $3.48MM | $4.05MM |
| Investing Cash Flow | $-17.27MM | $-3.31MM | $-219.35MM |
| Financing Cash Flow | $-0.69MM | $187.07MM | $164.02MM |
| Earnings Per Share** | $-2.74 | $-1.82 | $-2.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.